Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Delphx Cap Mkts Inc
Thai Future Incorporation Pub CO Ltd
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
151.22
-3.99 (-2.57%)
Official Closing Price
Updated: 7:00 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom
↗
November 19, 2026
Novartis (NYSE:NVS) executives outlined a slate of upcoming drug-trial results and regulatory discussions across immunology, cardiovascular disease, oncology and neuroscience, while reiterating sales...
Via
MarketBeat
Topics
ETFs
Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven
↗
November 19, 2026
Novartis (NYSE:NVS) is applying artificial intelligence across drug research and clinical development, with executives reporting faster trial enrollment and drug candidate selection while cautioning...
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations
↗
November 19, 2026
Novartis (NYSE:NVS) expects annual sales growth of 5% from 2026 through 2031 and average mid-single-digit growth into the mid-2030s, as the drugmaker looks to offset patent expirations with newer...
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Intellectual Property
Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer’s Gene Therapy Dosing
↗
November 16, 2026
Voyager Therapeutics (NASDAQ:VYGR) expects a readout from its tau antibody study in the current quarter and plans to begin dosing patients in its Alzheimer’s gene therapy program in the coming months,...
Via
MarketBeat
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile
↗
September 26, 2026
Via
Chartmill
Ocular Therapeutix (NASDAQ:OCUL) reports sales below analyst estimates in Q3 2026 earnings, stock drops
November 09, 2026
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell short of the market’s revenue expectations in Q3 2026, with revenue falling 11....
Via
StockStory
Genmab (GMAB) Q3 2026 Earnings Call Transcript
↗
November 06, 2026
Strong royalties and pipeline progress, but litigation risks remain in focus.
Via
The Motley Fool
Topics
Earnings
REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript
↗
November 05, 2026
Royalty declines and a litigation gain shaped the quarter's results.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Novartis: 3 Key Takeaways for Long-Term Investors
↗
November 03, 2026
Operating margins are on track to hit 40% by 2029 as cost discipline accelerates alongside new drug launches.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Advances in Cancer Care Are Moving Closer to Home
October 29, 2026
(BPT) - Key takeaways:
Via
Brandpoint
Should You Buy Royalty Pharma Stock Before Nov. 4?
↗
October 29, 2026
Don't expect earnings day to sustain the stock's recent rally.
Via
The Motley Fool
What Novartis (NVS) Said on Its Q3 Earnings Call
↗
October 27, 2026
Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core...
Via
MarketBeat
Topics
ETFs
Earnings
Novartis (NVS) Q3 2026 Earnings Call Transcript
↗
October 27, 2026
Priority brands offset generic erosion as margin expands and pipeline advances.
Via
The Motley Fool
Topics
Earnings
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report
↗
October 27, 2026
Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker fell short.
Via
Investor's Business Daily
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
↗
October 23, 2026
Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates and MRI lesion...
Via
MarketBeat
Topics
ETFs
If Economists Are Correct About the Future of AI, Here Are 2 Global ETFs to Buy -- and 2 to Avoid
↗
October 22, 2026
A recent survey shows reasons to be bullish on international stocks. But some global ETFs look more bullish than others.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Economy
Where You Live Shouldn't Limit Your Cancer Care
October 20, 2026
(BPT) - Key takeaways:
Via
Brandpoint
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
October 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
↗
October 01, 2026
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.
Via
The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
At the Longevity Investors Conference in Gstaad, Investors Test Which Longevity Claims Hold Up
September 29, 2026
DATELINE]As longevity research moves from animal models into human trials, investors are asking a sharper question: what is science, and...
Via
Newsfile
Leaders Face Stark Warning from Silicon Valley Veteran – The Old Way of Working is Dead
September 25, 2026
Via
Get News
Topics
Artificial Intelligence
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
↗
September 17, 2026
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
Via
The Motley Fool
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022
↗
September 16, 2026
The pharmaceutical giant's track record in past bear markets is fairly impressive.
Via
The Motley Fool
Topics
Economy
Intellectual Property
Stocks
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
↗
September 16, 2026
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.
Via
Investor's Business Daily
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
↗
September 15, 2026
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
Via
The Motley Fool
Topics
ETFs
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
↗
September 14, 2026
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
Via
The Motley Fool
Amgen Drops 10% on a Trial It Didn't Even Run
↗
September 11, 2026
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
Via
MarketBeat
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
↗
September 11, 2026
Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit